CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel W. Neal, Thomas Newsom-Davis, Daniel C. Christoph et al.|Journal of Clinical Oncology|2024Cited by 57